SCN Plans to Sell Additional Shares in Scandivir

As communicated to the market in previous press releases, for example on March 30, 2009, Scandinavian Clinical Nutrition AB (SCN) has sold parts of the company’s shareholding in Scandivir AB in order to strengthen the company’s financial situation. With reference to the article in the Norwegian financial magazine Finansavisen today, SCN hereby clarifies that the company plans to sell additional parts or all of the company’s shares in Scandivir, in line with the previously communicated strategy. In the previous transactions, Scandivir has been valued to +/- MSEK 100. SCN has good reason to believe that future transactions can be carried out at approximately the same valuation.